Open AccessLong‐acting recombinant follicle‐stimulating hormone in random‐start ovarian stimulation protocols for fertility preservation in women with cancer
Author(s) -
Sarais Veronica,
Paffoni Alessio,
Pagliardini Luca,
Filippi Francesca,
Martinelli Fabio,
Mangili Giorgia,
Candiani Massimo,
Papaleo Enrico
Publication year - 2017
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.13146
Subject(s) - medicine , fertility preservation , recombinant dna , fertility , controlled ovarian hyperstimulation , follicle stimulating hormone , hormone , stimulation , gynecology , oocyte , andrology , ovulation induction , endocrinology , luteinizing hormone , pregnancy , infertility , ovulation , biology , embryo , population , biochemistry , genetics , environmental health , gene , microbiology and biotechnology
The objective of this study was to assess the effectiveness and potential benefits of the use of long‐acting recombinant follicle‐stimulating hormone ( FSH ) in a random‐start protocol for fertility preservation in women with cancer. Material and methods This is a retrospective before‐and‐after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random‐start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long‐acting recombinant FSH . The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected. Results Compared with daily recombinant FSH , the use of the long‐acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ. Conclusions The use of long‐acting recombinant FSH in random‐start protocols for fertility preservation appears to be a valuable option.